| Objective To explore the clinical efficacy of Duzhong Zhuanggu capsule combined with raloxifene in the treatment of postmenopausal osteoporosis. Methods 158 cases of postmenopausal osteoporosis were randomly divided into treatment group (n=79) and control group (n=79). The control group was treated with raloxifene, and the treatment group was treated with Duzhong Zhuanggu capsule combined with raloxifene for 12 months. The bone mineral density of the femoral neck, lumbar spine and hip, the levels of serum bone alkaline phosphatase (BALP), type I procollagen N-terminal propeptide (PINP) , serum type I collagen cross-linked C-terminal peptide (S-CTX), alkaline phosphatase (ALP) and osteocalcin (BGP) were measured before and after treatment. The total effective rate and adverse drug reactions were recorded in both groups. Results The total effective rate of the treatment group was 93.67%, while that of the control group was 78.48%, there was significant difference between the two groups (P<0.05). After 12 months treatment, the BMD of the femoral neck, hip and lumbar in both groups increased to some extent. The changes of bone mineral density in the treatment group were more obvious than those in the control group (P<0.05). At the same time, the levels of serum S-CTX, PINP and ALP in each group were decreased, the levels of BALP and BGP were increased, while the changes in the treatment group were more obvious. There was significant difference between the two groups (P<0.05). The difference between two groups of patients on adverse drug reactions was statistically significant (P>0.05). Conclusion Duzhong Zhuanggu capsule combined with raloxifene in the treatment of postmenopausal osteoporosis is safe and effective, which is better than raloxifene alone. |